List of Orgovyx drug patents

Orgovyx is owned by Myovant Sciences.

Orgovyx contains Relugolix.

Orgovyx has a total of 6 drug patents out of which 0 drug patents have expired.

Orgovyx was authorised for market use on 18 December, 2020.

Orgovyx is available in tablet;oral dosage forms.

Orgovyx can be used as treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent, treatment of adult patients with advanced prostate cancer.

Drug patent challenges can be filed against Orgovyx from December, 2024.

The generics of Orgovyx are possible to be released after 29 September, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(11 months from now)

US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(11 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735401 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(1 year, 4 days from now)

US10350170 MYOVANT SCIENCES Solid preparation
Feb, 2036

(13 years from now)

US10449191 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

US10786501 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic